Head-to-head evidence
guselkumab vs ustekinumab-stba (Steqeyma)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline
guselkumab · Tremfya
Marketed by Johnson & Johnson
QUASAR/GALAXI · Phase 3 · completed
Only IL-23i to beat ustekinumab head-to-head on endoscopy in a registrational trial — strong differentiator.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: February 2027 · NCT06260163 (registry estimate)
ustekinumab-stba (Steqeyma)
Marketed by Celltrion
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Crohn's Disease
Shared mechanism: IL-23 p19 · full Crohn's Disease pipeline
guselkumab · Tremfya
Marketed by Johnson & Johnson
QUASAR/GALAXI · Phase 3 · completed
Only IL-23i to beat ustekinumab head-to-head on endoscopy in a registrational trial — strong differentiator.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: March 2027 · NCT05347095 (registry estimate)
ustekinumab-stba (Steqeyma)
Marketed by Celltrion
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: guselkumab's landscape · ustekinumab-stba (Steqeyma)'s landscape